Olamkicept (FE 999301) is a selective inhibitor of the soluble interleukin 6 ( sIL-6R )/ IL-6 complex. Olamkicept is a soluble gp130-Fc-fusion-protein and anti-inflammatory agent In Vitro Olamkicept (10 µg/mL, 60 min) inhibits IL-6 trans-signaling mediated STAT3 activation in HRECs . Olamkicept (10 µg/mL, 60 min) inhibits IL-6 trans-signaling induced increase in H 2 O 2 levels in HRECs . Olamkicept (10 µg/mL, 60 min) inhibits IL-6 trans-signaling induced apoptosis in HRECs . Olamkicept (0-1 µg/mL) inhibits IL-11/recombinant sIL-11R induced proliferation of Ba/F3-gp130 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis Cell Line: Human retinal endothelial cells (HRECs) Concentration: 10 µg/mL Incubation Time: 60 min Result: Inhibited IL-6/sIL-6R induced increase in STAT3 phosphorylation. In Vivo Olamkicept (sgp130Fc) (0.01-10 mg/kg, s.c.) increases survival in a cecal ligation and puncture (CLP) sepsis mice model. Olamkicept (0.5 mg/kg, i.p.) suppresses inflammation and increases survival rate in cecum ligation and puncture (CLP)-induced mice with sepsis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Cecal ligation and puncture (CLP) sepsis mice modelDosage: 0.01, 0.1, 1, 10 mg/kg Administration: s.c. Result: Improved survival rate and physical activity. IC50& Target:sIL-6R/IL-6 Complex